Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System".